CAV1和KRT5是前列腺癌的潜在目标
Liuxiong Guo1,2, Yixuan Liu3, Tao Yang2
1Department of Graduate School, Hebei Medical University, Shijiazhuang, China.
Medicine
|December 8, 2023
概括
这项研究表明,CAV1和KRT5在前列腺癌中表达高,与患者的治疗结果较差相关. 了解这些基因表达提供了对前列腺癌进展和潜在治疗点的新见解.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 前列腺癌是男性泌尿器官系统的流行恶性瘤.
- 在前列腺癌的发展和进展中,CAV1和KRT5的具体作用尚不清楚.
研究的目的:
- 为了研究CAV1,KRT5和前列腺癌之间的关系.
- 通过生物信息学和实验方法识别与前列腺癌有关的关键基因和途径.
主要方法:
- 对基因表达综合 (GEO) 数据集的分析 (GSE114740,GSE200879).
- 差异基因表达分析,加权基因共同表达网络分析和蛋白质-蛋白质相互作用网络构建.
- 功能性丰富分析 (基因本体学,KEGG),比较性毒基因组学数据库分析,以及对CAV1和KRT5表达的西方斑点验证.
主要成果:
- 确定了770个差异表达基因 (DEG),这些基因在PI3K-Akt,MAPK和ErbB信号传递等途径中得到丰富.
- 发现CAV1,KRT5和其他核心基因在前列腺癌组织中高度表达.
- 较高的CAV1和KRT5表达与瘤进展,转移和更糟糕的预后有关.
结论:
- CAV1和KRT5在前列腺癌中显著上调,并作为预后不良的潜在生物标志物.
- 这些发现凸显了特定信号通路在前列腺癌发病过程中的参与.
- 对CAV1和KRT5的进一步研究可能会导致前列腺癌的新疗法策略.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Enzyme-linked Receptors
78.5K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K


